Jonathan S. Rosenblum
Jonathan Rosenblum is Vice President, Research at ActivX Biosciences where he oversees early-stage drug discovery. At ActivX, he has exploited chemical proteomics for the discovery of differentiated small-molecule drugs. He has pursued a wide variety of therapeutic targets, helping to identify and advance several first- or best-in-class small molecules. He was ActivX’s project leader for the discovery and development of dipeptidyl peptidase 4 inhibitors, which resulted in advancement of KRP-104 through worldwide phase II clinical study. Prior to ActivX, Jonathan was an NIH postdoctoral fellow at Rockefeller University, where he studied protein translocation with Nobel Laureate Günter Blobel. He received his PhD in biochemistry at The Scripps Research Institute as an NSF predoctoral fellow and graduated magna cum laude from the University of Pennsylvania with a BA in Chemistry.